<DOC>
	<DOCNO>NCT01251640</DOCNO>
	<brief_summary>Open-label , uncontrolled , Phase I/II study evaluate safety efficacy BAY86-9766 plus gemcitabine locally advanced , unresectable metastatic pancreatic cancer . Phase I : Dose escalation study investigate 20 , 30 50 mg BAY86-9766 plus gemcitabine ( 1000mg/m2 ) ; determination maximum tolerate dose recommended phase 2 dose . Phase II : Determination response ( RECIST 1.1 ; primary endpoint ) . Secondary endpoint : response duration , disease control rate , time progression , progression-free survival , overall survival , safety tolerability . Tumor assessment Screening every 8 week . ; Safety evaluation Screening weekly throughout study ; Safety follow-up visit 30 day last dose study treatment ; Survival follow monthly 8 month LPFV .</brief_summary>
	<brief_title>Combination With Gemcitabine Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Male female patient â‰¥18 year age Histological cytologically confirm locally advance , inoperable metastatic pancreatic adenocarcinoma amenable curative radiotherapy surgery Patients must least one unidimensional measurable lesion CT MRI accord RECIST , Version 1.1 Resolution acute toxic effect prior local treatment Common Terminology Criteria Adverse Events ( CTCAE ) Grade &lt; /= 1 Eastern Cooperative Oncology Group performance status ( ECOG PS ) &lt; /= 2 Patient cardiac function , within normal range , measure echocardiogram Known history , symptomatic metastatic brain meningeal tumor History cardiac disease Active clinically serious infection Clinically significant ( ie . symptomatic ) peripheral vascular disease Pregnant lactate woman ; woman childbearing potential employ adequate contraception Use strong inhibitor inducer CYP3A4 Prior systemic therapy metastatic locally advanced , unresectable pancreatic cancer , malignancy Previous gemcitabine 5fluorouracil ( 5FU ) give concurrently radiosensitizers radiation therapy adjuvant intention give within 6 month start study treatment Thrombotic embolic event within 6 month prior start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>pancreatic cancer ,</keyword>
	<keyword>MEK-inhibitor</keyword>
</DOC>